Literature DB >> 31156971

Cross-sectional analysis of retrospective case series of hospitalisations for gastropathy caused by non-steroidal anti-inflammatory treatment: risk factors and gastroprotection use.

José Luis Marco Garbayo1, Manuel Koninckx Cañada1, Isabel Pérez Castelló1, María Teresa Faus Soler1, Rosa Fuster Torres2, Mar Moncho Escrivà1.   

Abstract

OBJECTIVES: To analyse the risk factors of gastropathy caused by using non-steroidal anti-inflammatory drugs (NSAIDs) in detected hospital admissions and to analyse the use of gastroprotective treatment concerning these risk factors.
METHODS: A retrospective observational study was carried out in the framework of an integral risk management plan of drugs and proactive pharmacovigilance of hospital admissions for NSAID-induced gastropathy occurring between 2011 and 2015. Cases were identified after reviewing the ICD-9 codes related to NSAID-induced gastropathy in hospital discharge reports. Various biometric, clinical and pharmacotherapeutic variables of each patient were registered. The gastroprotective criteria set out in the therapeutic decision algorithm of the Valencian Health System were followed.
RESULTS: 62 hospital admissions for NSAID-induced gastropathy were detected. The mean length of stay was 5.3±3.8 days. Ibuprofen was the most prevalent NSAID (28 cases, 45.2%). 24 cases (38.7%) took NSAIDs in the week before hospitalisation. The prevalence of relevant risk factors for gastropathy were age >60 years (37 cases, 59.7%), concomitant medication (24 cases, 38.7%) and a history of peptic ulcer (9 cases, 14.5%). 41 patients (66.1%) met gastroprotective major criteria, 18 of whom (43.9%) were using a proton pump inhibitor following a prevention plan.
CONCLUSIONS: In this study all relevant gastroprotective criteria were associated with the use of gastroprotection in detected hospital admissions for NSAID-induced gastropathy. However, a lack of gastroprotection was observed in a large number of detected cases with the criteria to use it. The feedback of our results to health area agents can serve to reinforce the safe use of NSAIDs.

Entities:  

Keywords:  acetylsalicylic acid; anti-ulcer agents; hospitalization; metamizole; nonsteroidal anti-inflammatory agents; pharmacovigilance; risk factors; safety; upper gastrointestinal bleeding

Year:  2016        PMID: 31156971      PMCID: PMC6451491          DOI: 10.1136/ejhpharm-2016-001087

Source DB:  PubMed          Journal:  Eur J Hosp Pharm        ISSN: 2047-9956


  23 in total

Review 1.  [Clinical strategy to prevent the gastrointestinal adverse effects of nonsteroidal anti-inflammatory agents].

Authors:  A Lanas; E Martin-Mola; J Ponce; F Navarro; J M Piqué; F J Blanco
Journal:  Gastroenterol Hepatol       Date:  2003-10       Impact factor: 2.102

Review 2.  [Consensus of a group of Mexican experts: efficacy and safety of metamizol (Dipirone)].

Authors:  Heriberto Arcila-Herrera; Sergio Barragán-Padilla; José Rafael Borbolla-Escoboza; Antonio Canto-Solís; Gilberto Castañeda-Hernández; Maximiliano de León-González; Miguel Angel Genis-Rondero; Vinicio Granados-Soto; José Luis Gutiérrez-García; Sonia Hernández-Hernández; Alicia Kassian-Rank; Victor Lara-Perera; Jorge Bernardo Vargas-Correa
Journal:  Gac Med Mex       Date:  2004 Jan-Feb       Impact factor: 0.302

3.  Underutilization of gastroprotection for at-risk patients undergoing percutaneous coronary intervention: Spain compared with the United States.

Authors:  R Casado-Arroyo; J M Scheiman; M Polo-Tomas; S D Saini; A Del Rio; E Guastello; A Lanas
Journal:  Aliment Pharmacol Ther       Date:  2010-09       Impact factor: 8.171

4.  [Trends of non-steroidal anti-inflammatory drugs use in Spain, 1990 through 2003].

Authors:  F J de Abajo; J García del Pozo; A del Pino
Journal:  Aten Primaria       Date:  2005-11       Impact factor: 1.137

5.  Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations.

Authors:  A Lanas; L A García-Rodríguez; M T Arroyo; F Gomollón; F Feu; A González-Pérez; E Zapata; G Bástida; L Rodrigo; S Santolaria; M Güell; C M de Argila; E Quintero; F Borda; J M Piqué
Journal:  Gut       Date:  2006-05-10       Impact factor: 23.059

Review 6.  Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s.

Authors:  S Hernández-Díaz; L A Rodríguez
Journal:  Arch Intern Med       Date:  2000-07-24

Review 7.  Risk factors for gastrointestinal ulcers caused by nonsteroidal anti-inflammatory drugs (NSAIDs)

Authors:  N Agrawal
Journal:  J Fam Pract       Date:  1991-06       Impact factor: 0.493

8.  Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data.

Authors:  S C Lewis; M J S Langman; Joan-Ramon Laporte; John N S Matthews; Michael D Rawlins; Bengt-Erik Wiholm
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

9.  [Prescribing non-steroidal antiinflammatory drugs and gastrointestinal protection in primary care].

Authors:  Paloma Carrillo Santiesteve; Ester Amado Guirado; Josep Antoni de la Fuente Cadenas; Enriqueta Pujol Ribera; Cèlia Tajada; Silvia Calvet; Clara Pareja Rossell
Journal:  Aten Primaria       Date:  2008-11       Impact factor: 1.137

10.  Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents.

Authors:  Joan-Ramon Laporte; Luisa Ibáñez; Xavier Vidal; Lourdes Vendrell; Roberto Leone
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

View more
  1 in total

1.  Non-steroidal anti-inflammatory drugs and gastroprotection in primary health care users.

Authors:  Driton Shabani; Ardiana Murtezani; Bernard Tahirbegolli; Argjira Juniku-Shkololli; Zana Ibraimi
Journal:  Med Pharm Rep       Date:  2020-07-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.